John Huettner

iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate

Retrieved on: 
Tuesday, August 16, 2022
Dai, Glycosylation, COVID-19 vaccine, Capsid, D-VT, Virus, CEO, GLOBE, Death, SEC, Research, Marketing, Infection, N, Sale, John Huettner, Congress, COVID-19, DNA, Administration, Epitope, Partnership, Vaccine, Immunity, Reconfigurable manufacturing system, CDMO, COVID, Hydroponics, Cancer, Global Goal: Unite for Our Future, Severe acute respiratory syndrome coronavirus 2, Time, United States Senate Committee on Appropriations, FDA, Identification, Legislation, BioRxiv, CGMP, IND, Committee, Chief executive officer, Company, MPH, Virology, Protein, Global health, Pharmaceutical industry, MD, Dutta

BRYAN, Texas, Aug. 16, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today provided an update on IBIO-202, its next-generation vaccine candidate under development for multi-variant COVID-19 disease.

Key Points: 
  • BRYAN, Texas, Aug. 16, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System, today provided an update on IBIO-202, its next-generation vaccine candidate under development for multi-variant COVID-19 disease.
  • In November 2020, iBio began exploring a second-generation COVID-19 vaccine program based on the N protein.
  • 2 Dutta, N. K., Mazumdar, K. & Gordy, J. T. The Nucleocapsid Protein of SARSCoV-2: A Target for Vaccine Development.
  • The Companys wholly-owned subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with Glycaneering Development Services for advanced recombinant protein design.

iBio Announces Progression of Vaccine Program for Multi-Variant COVID-19 Disease

Retrieved on: 
Wednesday, January 26, 2022
Dai, Food, Capsid, Cross, Calendar, COVID, Vaccine, Virology, DNA, World Health Organization, COVID-19, Vaccination, N, IND, SEC, Research, World, BioRxiv, Sale, Severe acute respiratory syndrome coronavirus 2, Epitope, Identification, Virus, CDMO, Immunization, Infection, Company, Cancer, DVM, Protein, John Huettner, Marketing, Immunity, Hydroponics, Glycosylation, COVID-19 vaccine, GLOBE, Omicron, FDA, Injection, Pharmaceutical industry

iBio recently received the U.S. Food and Drug Administrations (FDA) response to its pre-investigational new drug (IND) package for IBIO-202.

Key Points: 
  • iBio recently received the U.S. Food and Drug Administrations (FDA) response to its pre-investigational new drug (IND) package for IBIO-202.
  • In November 2020, iBio began exploring a second-generation COVID vaccine program based upon the nucleocapsid protein.
  • Today, iBio announced that, based on feedback it has received from the FDA, it will pursue IND-enabling studies for IBIO-202.
  • More information on the COVID-19 vaccine program can be found on the Companys website .

Omicron Variant Underscores Need for New COVID Vaccine Candidates Like IBIO-202

Retrieved on: 
Monday, November 29, 2021
Dai, Capsid, Sale, Regulation of tobacco by the U.S. Food and Drug Administration, Cancer, Protein, Virus, Â, Access, BioRxiv, Company, COVID-19 vaccine, WHO, World, Severe acute respiratory syndrome coronavirus 2, Glycosylation, Hydroponics, Injection, Agency, SEC, Vaccine, COVID-19, Virology, DVM, U.S. FDA, Research, DNA, GLOBE, Marketing, N, Identification, Public health, Epitope, Infection, John Huettner, CDMO, Food, COVID, Animal

BRYAN, Texas, Nov. 29, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today announced an update for its lead COVID-19 vaccine program, IBIO-202, in light of the emergence of the Omicron (B.1.1.529) variant of SARS-CoV-2.

Key Points: 
  • Second, the N protein is more highly conserved than the S protein, and therefore, new variants may be less likely to escape vaccine protection.
  • We are developing our COVID vaccine candidate in line with an approach we call our DAVi strategy, which stands for improved Durability, Access and Variant-inclusion.
  • Finally, we expect an N-based vaccine to provide better protection against future variants, given how mutable the S protein appears to be.
  • In November 2020, iBio made the decision to begin exploring a second-generation COVID vaccine program based upon the nucleocapsid protein.